<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298749</url>
  </required_header>
  <id_info>
    <org_study_id>GX-P1-001</org_study_id>
    <nct_id>NCT04298749</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of GX-P1 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-P1 After Single IV Infusion in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, double-blind, placebo-controlled, phase I study with healthy
      male volunteers receiving ascending single dose of GX-P1
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by AEs</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Safety and tolerability will be assessed by monitoring AEs and performing physical/clinical examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, Maximum observed concentration</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, Time to maximum observed concentration</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Time to maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2, Elimination half life of GX-P1</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Elimination half life of GX-P1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf), Area under the concentration-time curve from time zero extrapolated to infinite time</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Area under the concentration-time curve from time zero extrapolated to infinite time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of T cells</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Change of T cell subsets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent anti-drug antibody(ADA) formation</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Treatment Emergent anti-drug antibody(ADA) formation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>GX-P1 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-P1 dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GX-P1 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-P1 dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GX-P1 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-P1 dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GX-P1 dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-P1 dose level 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-P1 or Placebo (dose level 1)</intervention_name>
    <description>GX-P1 dose level 1 or placebo</description>
    <arm_group_label>GX-P1 dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-P1 or Placebo (dose level 2)</intervention_name>
    <description>GX-P1 dose level 2 or placebo</description>
    <arm_group_label>GX-P1 dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-P1 or Placebo (dose level 3)</intervention_name>
    <description>GX-P1 dose level 3 or placebo</description>
    <arm_group_label>GX-P1 dose level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-P1 or Placebo (dose level 4)</intervention_name>
    <description>GX-P1 dose level 4 or placebo</description>
    <arm_group_label>GX-P1 dose level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Capable of understanding and complying with the requirements of the study and have
             voluntarily signed the informed consent form (ICF)

          2. Healthy male volunteers aged 19-45 years within screening periods

          3. Body weight of 50-90 kg, and body mass index (BMI) of 18.0-30.0 kg/m2

          4. Healthy subjects as determined by medical history, physical examination vital signs,
             ECG and clinical laboratory testing

        Exclusion Criteria:

          1. Any clinical significant pancreatic, hepatic, renal, gastrointestinal, cardiovascular,
             respiratory, hematological, central nervous system disease or other significant
             diseases which might influence either the safety of the subject or the absorption,
             metabolism or excretion of the active agent under investigation

          2. History of or current disease evidence including malignant tumor

          3. History of allergy/hypersensitivity or ongoing allergy/hypersensitivity to any drug

          4. Have participated in another clinical trial with investigational drug within 180 days
             prior to screening period

          5. Positive for HCV antibody, HBsAg, or HIV antibody at screening period

          6. Other clinically significant abnormalities which make subject unsuitable for inclusion
             this study judged by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yung Jung Choi, Ph.D</last_name>
    <phone>82-31-628-3210</phone>
    <email>yunjung.choi@genexine.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

